Contact | Print version | PDF version | Send article | RSS feed

Saltigo targets Japanese custom manufacturing market

02 Jul 2009 - Saltigo GmbH targets Japanese custom manufacturing market, presenting its portfolio of services at Interphex/Pharma-i Japan Exhibition in Tokyo. Saltigo’s CEO Wolfgang Schmitz emphasizes: "This is Asia’s largest pharmaceutical industry event and has an excellent reputation for attracting key decision makers from the industry. The Asian market and Japan in particular is becoming increasingly important for Saltigo. We already enjoy a good level of business activity in Japan across all market sectors, especially those serving life science industries.”
 
Japan is well-known for its commitment to new technologies and innovative products. This coupled with extremely stringent demands for higher tier performance is perfectly in line with Saltigo’s strategy to expand service offerings to this market. Saltigo, the wholly-owned subsidiary of specialty chemicals company LANXESS, has completed a Euro 10 million investment in early 2008 for a facility focused on the production of advanced intermediates and active ingredients under CGMP (Current Good Manufacturing Practice). The unit based in Leverkusen/Germany has a total capacity of more than 200 metric tons per year and provides a high degree of flexibility in terms of reactor volumes which range from 2.5 to 8 cubic meters.
 
To complement commercial scale manufacturing capacity, LANXESS Corporation also operates a site for Saltigo in Redmond (Washington, United States) targeting the field of active ingredient research and projects in the pre-clinical and early clinical phases. Its initial capacity was expanded again during 2008, and extends in particular Saltigo's ability to meet growing outsourcing requirements.
 
Osaka-based Sota Kurita, Business Development Manager for Japan, comments: "With the globalization of today’s pharmaceutical business, a significant proportion of new drug candidate compounds created in Japan first undergo clinical testing in the US. It has therefore become increasingly important to have an investigational new drug supply site in the US that can offer not just FDA compliant manufacture but also comprehensive support in areas such as quality assurance and the regulatory registration process.”